Discovering next generation antibody-based therapeutics addressing challenging targets for the treatment of cancer.
Our Company
QLSF Biotherapeutics is an innovative immuno-oncology startup company in South San Francisco. Our research and development are focused on a diversified oncology portfolio, with strong financial and clinical development support from a leading pharmaceutical company.
Our Team
We are an experienced team of scientists with expertise in antibody
engineering, protein science, immuno-oncology and
preclinical in vivo models.
Our Leadership
Shihao Chen, PhD
CEO, Co-Founder
Hieu Van Tran, MS
Co-Founder
Alan Wahl, PhD
Scientific Advisor
Join Our Team
We are a science-driven company and always welcome scientists with talent and expertise.
Please send your cover letter and resume to [email protected].
Current Openings
Investors
QLSF Biotherapeutics is open to co-development, strategic partnerships or out-licensing opportunities to fully leverage our platform and programs.
For additional information on QLSF programs please contact [email protected].
News
November 18, 2021 | QLSF Biotherapeutics to Present Preclinical Data of 3 Clinical Stage Programs at the 2022 AACR Annual Meeting
Poster presentations will feature QL301 PD-L1 x 4-1BB bispecific antibody, QL401 PD-L1 x 4-1BB bispecific antibody, and QL415 PD-L1 IL-15 cytokine fusion protein.
November 2, 2021 | First Patient Dosed in a Phase 1 Study of QL415 PD-L1 x IL-15 Cytokine Fusion Protein
The phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and preliminary Efficacy of QL415 as a monotherapy in patient with advanced malignant tumors.
October 20, 2021 | First Patient Dosed in a Phase 1 Study of QL301 PD-L1 x 4-1BB Bispecific Antibody
The phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and preliminary Efficacy of QL301 as a monotherapy in patient with advanced malignant tumors.